The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Histone Deacetylase Inhibitors Market Expected To Scale Between 2026 And 2030?
The histone deacetylase inhibitors market has experienced significant growth in recent years. This market is projected to expand from $1.29 billion in 2025 to $1.39 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. The historical growth can be attributed to the early success of hdac inhibitors in hematological malignancies, an increasing understanding of epigenetic regulation in disease, the availability of approved first-generation hdac inhibitors, the expansion of cancer research infrastructure, and heightened investment in targeted cancer therapies.
The histone deacetylase inhibitors market size is anticipated to experience substantial growth in the coming years. It is projected to expand to $1.81 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.8%. This expansion during the forecast period is driven by several factors, including the rising worldwide incidence of cancer, an expanding pipeline of epigenetic-based therapies, an increased emphasis on precision oncology approaches, the broadening of clinical trials for neurological and inflammatory indications, and the demand for more selective and safer epigenetic drugs. Prominent trends expected in the forecast period encompass the increasing integration of HDAC inhibitors into oncology treatment regimens, a growing focus on selective and isoform-specific HDAC inhibitors, the rising adoption of combination therapies that involve HDAC inhibitors, the extension of HDAC inhibitor research beyond cancer indications, and consistent growth in oral HDAC inhibitor formulations.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17170&type=smp
What Major Factors Are Driving The Histone Deacetylase Inhibitors Market Forward?
The anticipated increase in cancer cases is expected to drive the growth of the histone deacetylase inhibitors market moving forward. This rising incidence of cancer is primarily attributed to the world’s aging populations, increased exposure to risk factors such as tobacco, diet, and environmental pollutants, and advancements in diagnostic techniques leading to earlier and more frequent detection. Histone deacetylase inhibitors treat cancer by altering chromatin structure, which leads to the activation of tumor suppressor genes and the suppression of oncogenes, thereby inducing cell cycle arrest and programmed cell death (apoptosis) in cancer cells. For instance, in February 2024, the World Health Organization, a US-based intergovernmental organization, predicted approximately 35 million new cancer cases by 2050, representing a 77% increase from the estimated 20 million cases in 2022. Therefore, the escalating incidence of cancer is a significant driver for the growth of the histone deacetylase inhibitors market.
How Is Segmentation Applied In The Histone Deacetylase Inhibitors Market Segment Analysis?
The histone deacetylase inhibitors market covered in this report is segmented –
1) By Classification: Class I Histone Deacetylases (HDACs), Class II Histone Deacetylases (HDACs), Class III Histone Deacetylases (HDACs), Other Classifications
2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Oncology, Neurology, Other Applications
5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Class I Histone Deacetylases (HDACs): HDAC1 Inhibitors, HDAC2 Inhibitors, HDAC3 Inhibitors, HDAC8 Inhibitors
2) By Class II Histone Deacetylases (HDACs): HDAC4 Inhibitors, HDAC5 Inhibitors, HDAC6 Inhibitors, HDAC7 Inhibitors, HDAC9 Inhibitors, HDAC10 Inhibitors
3) By Class III Histone Deacetylases (HDACs): Sirtuin 1 (SIRT1) Inhibitors, Sirtuin 2 (SIRT2) Inhibitors, Sirtuin 3 (SIRT3) Inhibitors, Sirtuin 4 (SIRT4) Inhibitors, Sirtuin 5 (SIRT5) Inhibitors, Sirtuin 6 (SIRT6) Inhibitors, Sirtuin 7 (SIRT7) Inhibitors
4) By Other Classifications: Dual-acting HDAC Inhibitors, Pan-HDAC Inhibitors, Selective HDAC Inhibitors, Combination Inhibitors (HDAC + Other Mechanisms)
What Trends Are Shaping The Future Of The Histone Deacetylase Inhibitors Market?
Leading companies in the histone deacetylase inhibitors market are concentrating on developing innovative product formulations, such as oral histone deacetylase (HDAC) inhibitors, to expand treatment options and improve patient convenience and compliance. An oral histone deacetylase (HDAC) inhibitor is a medication taken by mouth that targets HDAC enzymes involved in gene regulation, with potential uses in treating various diseases, including cancer and inflammatory conditions. For instance, in March 2024, Italfarmaco S.p.A., an Italy-based pharmaceutical company, received Food and Drug Administration approval for Duvyzat (givinostat), an oral histone deacetylase (HDAC) inhibitor, for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 6 years and older. Duvyzat is a histone deacetylase (HDAC) inhibitor that mitigates the sequence of events leading to muscle damage, potentially slowing the progression of muscle deterioration associated with DMD. By inhibiting HDAC overactivity, it reduces inflammation and fibrosis while promoting muscle fiber regeneration. The approval is based on the pivotal phase 3 EPIDYS trial, which met its primary endpoint, demonstrating that patients on Duvyzat showed a statistically significant decrease in the time to complete the four-stair climb assessment compared to placebo.
Who Are The Companies Participating In The Histone Deacetylase Inhibitors Market Environment?
Major companies operating in the histone deacetylase inhibitors market are Syndax Pharmaceuticals Inc., MEI Pharma Inc., Italfarmaco S.p.A., Shenzhen Chipscreen Biosciences Co. Ltd., Celgene Corporation, Spectrum Pharmaceuticals Inc., Curis Inc., Onxeo SA, Celleron Therapeutics, Forum Pharmaceuticals Inc., Merck & Co. Inc., AstraZeneca plc, Novartis AG, Eisai Co. Ltd., Karyopharm Therapeutics Inc., Medivir AB, Huya Bioscience International LLC, Crystal Genomics Inc., Midatech Pharma PLC, Regenacy Pharmaceuticals Inc.
Get The Full Histone Deacetylase Inhibitors Market Report:
Which Region Is The Leading Market For The Histone Deacetylase Inhibitors Market?
North America was the largest region in the histone deacetylase inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Histone Deacetylase Inhibitors Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Histone Deacetylase Inhibitors Market 2026, By The Business Research Company
Histone Deacetylase Inhibitors Market Report 2026
Histone Deacetylase Inhibitors Market Report 2026
Enzyme Inhibitor Market Report 2026
https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model